| Cat. No. |
Product Name |
Information |
| PC-61439 |
YM-359445
|
A highly potent, orally active VEGFR-2 inhibitor with IC50 of 8.5 nM, without activity against PKA, PKCα, PDK-1 and JNK3 (IC50>1 uM). |
| PC-61395 |
NVP-AAC789
|
A potent, selective VEGFR-2 tyrosine kinase inhibitor with IC50 of 20 nM, weakly inhibits VEGFR-1, 3 with IC50 of 180 and 380 nM. |
| PC-60958 |
PF-00337210
|
A potent, selective, ATP-competitive and orally bioavailable inhibitor of VEGFR-2 with Ki of 0.7 and 8.8 nM for unactivated and fully phosphorylated VEGFR-2, respectively. |
| PC-42768 |
MGCD-265 analog
|
An analog of MGCD-265, and an orally bioavailable multikinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.. |
| PC-42533 |
Brivanib alaninate
|
A prodrug of Brivanib, which is a dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively. |
| PC-42146 |
BFH-772
|
A potent, selective and orally active VEGFR2 tyrosine kinase inhibitor with IC50 of 3 nM. |
| PC-42472 |
Motesanib diphosphate
|
A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively. |
| PC-42824 |
Pazopanib hydrochloride
|
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for
VEGFR-1, -2, and -3, respectively. |
| PC-42453 |
Pazopanib
|
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for
VEGFR-1, -2, and -3, respectively. |
| PC-42448 |
Vatalanib free base
|
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ. |
| PC-42531 |
Regorafenib monohydrate
|
A potent multikinase inhibitor that potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays with nanomolar range (IC50=3-200 nM). |
| PC-42557 |
SU5416
|
A potent and specific VEGFR2 (KDR/Flk-1) inhibitor with IC50 of 1.04 uM. |
